Actin vs Mint Med
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Mint Med
Best for Cost-sensitive buyers seeking flat $159/mo 'all doses' compounded GLP-1 pricing without per-tier escalation, with HSA/FSA payment + no-membership pay-as-you-go model + LegitScript verification + verbatim FDA disclaimer. Strong fit for self-pay patients in any of the 36 listed states who value pricing transparency + cancel-anytime over premium clinical features.Starting at $117/mo
Side-by-Side Comparison
| Feature | Actin | Mint Med |
|---|---|---|
| Overall Score | 7.0/10 | ✓7.5/10 |
| Starting Price | $133/mo | ✓$117/mo |
| Editorial Rating | 3.5 ★ /5 | ✓3.8 ★ /5 |
| Features | 2 features | ✓12 features |
| States Available | 0 | ✓36 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Mint Med
Pros
- ✓**$159 'all doses' flat pricing** removes the typical DTC pattern of per-tier price escalation as patients titrate up — significantly more transparent vs competitors charging $99 starting then $200+ at higher doses
- ✓**No-membership model** — pay-as-you-go monthly with cancel-anytime + 48hr-notice — reduces sign-up friction
- ✓LegitScript Certified with publicly verifiable ID (44490960)
- ✓Verbatim FDA compounded-medication disclaimer published (meets WLR transparency standard)
- ✓36-state explicit list with full enumeration — strong coverage breadth
- ✓HSA/FSA eligible (uncommon in DTC compounded GLP-1)
- ✓Asynchronous telehealth in allowed states — faster intake vs synchronous-only competitors
- ✓Promotional code (175NOW) for First Six Weeks $175 = ~$117/mo effective — competitive intro tier
Cons
- ✗**Distinct from Mint Medical Clinic (mintmedicalclinic.com, Utah-only hybrid med spa)** — buyers searching 'Mint' may confuse the two providers. Both are in the WLR directory but represent fundamentally different business models.
- ✗Specific 503A/503B pharmacy partner NOT named
- ✗503A vs 503B compounding designation NOT specified
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Governing law / arbitration venue / corporate physical address NOT disclosed
- ✗Stated 35-state count vs enumerated 36-state list shows a minor inconsistency (one state appears double-counted or there's an off-by-one in the marketing copy)
- ✗Asynchronous telehealth model limits live-provider interaction in eligible states
Our Verdict
Mint Med edges out Actin with a higher overall score of 7.5/10 and is particularly strong for Cost-sensitive buyers seeking flat $159/mo 'all doses' compounded GLP-1 pricing without per-tier escalation, with HSA/FSA payment + no-membership pay-as-you-go model + LegitScript verification + verbatim FDA disclaimer. Strong fit for self-pay patients in any of the 36 listed states who value pricing transparency + cancel-anytime over premium clinical features.. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.